These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16782516)

  • 41. Drug eluting stents in the infrainguinal circulation.
    Machan L
    Tech Vasc Interv Radiol; 2004 Mar; 7(1):28-32. PubMed ID: 15071778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Unprotected left main disease managed with drug-eluting stents: long-term outcome of 100 patients with increased surgical risk.
    Wood FO; Saylors EK; Schneider JE; Jobe RL; Mann JT
    Catheter Cardiovasc Interv; 2008 Mar; 71(4):533-8. PubMed ID: 18307224
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial.
    Morice MC; Serruys PW; Barragan P; Bode C; Van Es GA; Stoll HP; Snead D; Mauri L; Cutlip DE; Sousa E
    J Am Coll Cardiol; 2007 Oct; 50(14):1299-304. PubMed ID: 17903626
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
    Lee JY; Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Park SW; Park SJ
    J Am Coll Cardiol; 2009 Aug; 54(9):853-9. PubMed ID: 19695467
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma levels following application of paclitaxel-coated balloon catheters in patients with stenotic or occluded femoropopliteal arteries.
    Freyhardt P; Zeller T; Kröncke TJ; Schwarzwaelder U; Schreiter NF; Stiepani H; Sixt S; Rastan A; Werk M
    Rofo; 2011 May; 183(5):448-55. PubMed ID: 21274828
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New drug-device combination helps keep arteries open.
    FDA Consum; 2003; 37(4):6. PubMed ID: 12971333
    [No Abstract]   [Full Text] [Related]  

  • 47. Drug-eluting stents soon to invade U.S. hospitals.
    DeJohn P
    Hosp Mater Manage; 2002 Oct; 27(10):1, 9-11. PubMed ID: 12385280
    [No Abstract]   [Full Text] [Related]  

  • 48. Sirolimus-eluting stents versus the superficial femoral artery: second round.
    Oliva VL; Soulez G
    J Vasc Interv Radiol; 2005 Mar; 16(3):313-5. PubMed ID: 15758126
    [No Abstract]   [Full Text] [Related]  

  • 49. [Prevention of recurrence after stent implantation in arterial occlusive diseases].
    Makoski HB
    Strahlenther Onkol; 1995 Mar; 171(3):178. PubMed ID: 7709336
    [No Abstract]   [Full Text] [Related]  

  • 50. Drug-eluting stents: factors governing local pharmacokinetics.
    Yang C; Burt HM
    Adv Drug Deliv Rev; 2006 Jun; 58(3):402-11. PubMed ID: 16616969
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessing drug elution technologies in the superficial femoral artery.
    Owens CD; Gasper WJ; Conte MS
    Panminerva Med; 2011 Mar; 53(1):37-49. PubMed ID: 21346703
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In-stent restenosis in the superficial femoral artery.
    Razzouk L; Aggarwal S; Gorgani F; Babaev A
    Ann Vasc Surg; 2013 May; 27(4):510-24. PubMed ID: 23535523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug-eluting stents: do we know enough about safety?
    Sindermann JR; Plenz G; Breithardt G
    Circulation; 2004 Jan; 109(3):E22. PubMed ID: 14744965
    [No Abstract]   [Full Text] [Related]  

  • 54. Mechanisms Underlying Drug Delivery to Peripheral Arteries.
    Li J; Tzafriri R; Patel SM; Parikh SA
    Interv Cardiol Clin; 2017 Apr; 6(2):197-216. PubMed ID: 28257768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Local paclitaxel delivery for treatment of peripheral arterial disease.
    Hawkins BM; Hennebry TA
    Circ Cardiovasc Interv; 2011 Jun; 4(3):297-302. PubMed ID: 21540442
    [No Abstract]   [Full Text] [Related]  

  • 56. Magnetically targeted delivery of therapeutic agents to injured blood vessels for prevention of in-stent restenosis.
    Chorny M; Fishbein I; Adamo RF; Forbes SP; Folchman-Wagner Z; Alferiev IS
    Methodist Debakey Cardiovasc J; 2012 Jan; 8(1):23-7. PubMed ID: 22891107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug-Eluting Stents Are the Default Strategy for Superficial Femoral Artery Intervention Now.
    Burket MW
    Circulation; 2016 Jan; 133(3):320-9; discussion 329. PubMed ID: 26783275
    [No Abstract]   [Full Text] [Related]  

  • 58. [Drug delivery system in cardiovascular drugs].
    Miyake F; Kamogawa A; Sakakibara M
    Nihon Rinsho; 1998 Mar; 56(3):737-41. PubMed ID: 9549366
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A polymer-metal composite stent.
    Kruse KR; Tanguay JF; Williams MS; Phillips HR; Stack RS; Zidar JP
    Semin Interv Cardiol; 1996 Mar; 1(1):46-8. PubMed ID: 9552492
    [No Abstract]   [Full Text] [Related]  

  • 60. Cardiovascular news. INHIBIT.
    SoRelle R
    Circulation; 2000 Dec; 102(25):E9050-1. PubMed ID: 11138603
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.